US2016331728A1PendingUtilityA1

Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence

62
Individually held — no corporate assignee on recordPriority: Sep 9, 2011Filed: Apr 12, 2016Published: Nov 17, 2016
Est. expirySep 9, 2031(~5.1 yrs left)· nominal 20-yr term from priority
Inventors:Bankole A. Johnson
C12Q 2600/156C12Q 2600/106C12Q 1/6883A61K 31/4178A61P 25/30
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides compositions and methods useful for diagnosing, treating, and monitoring alcohol dependence and disorders and susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders.

Claims

exact text as granted — not AI-modified
1 . A method of treating an addictive disease or disorder, comprising:
 administering to a patient in need thereof a therapeutically effective amount of an antagonist of the serotonin receptor 5-HT 3 , wherein the patient's serotonin transporter gene SLC6A4 is known to have a genotype selected from sets (a)-(q):   (a.) the AA genotype of rs1176719 and the AG genotype of rs1150226;   (b.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the AC genotype of rs17614942;   (c.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the LL genotype of 5411711PR, and the TT genotype of rs1042173;   (d.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;   (e.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;   (f.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the AC genotype of rs17614942 and the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;   (g.) the AA genotype of rs1176719 and the GG genotype of rs1176713;   (h.) the AA genotype of rs1176719 and the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;   (i.) the AA genotype of rs1176719 and the GG genotype of rs1176713 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;   (j.) the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;   (k.) the GG genotype of rs1176713 and the AG genotype of rs1150226 and the LL genotype of 5-HTTLPR and the TT genotype of rs1042173;   (l.) the genotype of rs1176713 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;   (m.) the GG genotype of rs1176713 and the AG genotype of rs1150226 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;   (n.) the AG genotype of rs1150226 and the AA genotype of rs1176719 and the AC genotype of rs17614942 and the GG genotype of rs1176713;   (o.) the AG genotype of rs1150226 and the AA genotype of rs1176719 and the GG genotype of rs1176713;   (p.) the AG genotype of rs1150226 and the AC genotype of rs17614942 and the GG genotype of rs1176713; and,   (q.) the AA genotype of rs1176719 and the AC genotype of rs17614942 and the GG genotype of rs1176713.   
     
     
         2 . The method of  claim 1 , wherein the patient is known to have genotype set (a). 
     
     
         3 . The method of  claim 1 , wherein the patient is known to have genotype set (h). 
     
     
         4 . The method of  claim 1 , wherein the patient is known to have genotype set (c). 
     
     
         5 . The method of  claim 1 , wherein the patient is known to have genotype set (d). 
     
     
         6 . The method of  claim 1 , wherein the patient is known to have genotype set (e). 
     
     
         7 . The method of  claim 1 , wherein the patient is known to have genotype set (f). 
     
     
         8 . The method of  claim 1 , wherein the patient is known to have genotype set (g). 
     
     
         9 . The method of  claim 1 , wherein the patient is known to have genotype set (h). 
     
     
         10 . The method of  claim 1 , wherein the patient is known to have genotype set (i). 
     
     
         11 . The method of  claim 1 , wherein the patient is known to have genotype set (j). 
     
     
         12 . The method of  claim 1 , wherein the patient is known to have genotype set (k). 
     
     
         13 . The method of  claim 1 , wherein the patient is known to have genotype set (l). 
     
     
         14 . The method of  claim 1 , wherein the patient is known to have genotype set (m). 
     
     
         15 . The method of  claim 1 , wherein the patient is known to have genotype set (n). 
     
     
         16 . The method of  claim 1 , wherein the patient is known to have genotype set (o). 
     
     
         17 . The method of  claim 1 , wherein the patient is known to have genotype set (p). 
     
     
         18 . The method of  claim 1 , wherein the patient is known to have genotype set (q). 
     
     
         19 . The method of  claim 1 , wherein the antagonist of the serotonin receptor 5-HT 3  is administered at a dosage ranging from 0.1 μg/kg to 1000 μg/kg per application. 
     
     
         20 . The method of  claim 19 , wherein the antagonist of the serotonin receptor 5-HT 3  is ondansetron. 
     
     
         21 - 28 . (canceled)

Join the waitlist — get patent alerts

Track US2016331728A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.